[Pharmacokinetics of urinary excretion of methotrexate (MTX) in patients with malignant tumors].
Pharmacokinetics of methotrexate renal elimination was investigated in patients with cancer given a single intravenous injection. Elimination coefficient ke (0.151 + 0.05 h-1) and half-life t0.5 (5.3 +/- 2.9 h) were calculated. A percentage of methotrexate dose eliminated with the urine was determined (26.0-97.1%) in both unchanged and bound forms. It was found that methotrexate is eliminated in the form of glucuronates and sulfates (2-25% of the administered dose). It was also noted, that pH of the urine exerts an effect on the amount of eliminated methotrexate.
Skibińska
L
L
Katedry i Zakładu Chemii Fizycznej AM im. K. Marcinkowskiego, Poznaniu.
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000652:urine; D016903:Drug Monitoring; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000652:urine; D006801:Humans; D007275:Injections, Intravenous; D008223:Lymphoma / Q000188:drug therapy* / Q000652:urine; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000652:urine*; D008875:Middle Aged; D013997:Time Factors
D008727:Methotrexate
Farmakokinetyka eliminacji metotreksatu (MTX) z moczem u chorych na nowotwory złośliwe.